Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma
Kinaset Therapeutics To Evaluate Candidate
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
